“엔비디아 다음, M7의 마지막 주인은 여깁니다” 넷플릭스보다 무서운 ‘바이오 구독’

Summary

The script delves into the explosive rise of subscription-based weight loss drugs like Ozempic, drawing parallels with platforms like Netflix in terms of their addictive, irreversible nature. It highlights how biotechnology has hacked human survival instincts to create a new, wealth-driven class divide, with the affluent using technology to control their biology. The video discusses the implications for investors, touching on breakthroughs in biopharma, challenges like needles and side effects, and opportunities in companies driving these innovations. Ultimately, it explores how wealth is reshaping human biology and the future of medicine in a rapidly evolving market.

Takeaways

• 😀 The emergence of an expensive, inescapable subscription service that’s far more costly than Netflix, with potentially billions of subscribers in the future.
• 😀 The pharmaceutical industry has introduced a new type of subscription-based service, exemplified by Wegovy (Ozenpic), which is not just a weight loss drug but part of a broader bio-tech revolution.
• 😀 Weight loss medication like Wegovy is not simply a diet aid, but a tool to reshape human biology, offering a life-altering solution, despite its high cost.
• 😀 Clinical studies suggest that when people stop using this drug, the weight they lost will return, emphasizing the inability to escape this 'subscription' for long-term weight management.
• 😀 This represents a shift where biological functions like appetite regulation are being hacked by advanced biotech to match modern survival needs.
• 😀 The pharmaceutical and biotech companies behind these drugs (like Eli Lilly and Novo Nordisk) are positioning themselves as the 'iOS' and 'Android' of the biological 'subscription' economy.
• 😀 Wealthy individuals who can afford these medications are effectively free from the lifelong struggle with obesity, transforming these drugs into symbols of status and self-control.
• 😀 A biological 'caste system' is emerging, where the rich have access to life-extending biotech solutions, while the poor continue to struggle with obesity and related health issues.
• 😀 Investors need to focus on companies that pass three key tests: can they treat more than just obesity, do they reduce injections (moving from weekly to monthly), and do they protect muscle mass during weight loss?
• 😀 Key players in the field include Eli Lilly, Novo Nordisk, and emerging companies like Petron and Hanmi Pharmaceutical, which are innovating in drug delivery systems and muscle-preserving weight loss treatments.
• 😀 However, the biotech industry is not without risks: policy changes, competition, and unknown long-term side effects (such as potential heart or thyroid issues) could significantly affect the market and stock prices.

Q & A

What is the main concept introduced in the script?

The script discusses the emergence of a new, expensive subscription model for weight loss drugs like Wegovy, comparing it to Netflix, but with a major twist: the subscription model for these drugs is essentially impossible to cancel, making it a long-term commitment for users.

Why is Wegovy referred to as a 'subscription model' for weight loss?

Wegovy is described as a 'subscription model' because, like a subscription service, users must continue paying to maintain the benefits. When they stop taking the drug, the weight they lost will return, implying that they cannot easily 'unsubscribe' from it.

What is the historical context behind our need to eat whenever food is available?

The script explains that humans evolved in an environment where food was scarce. As a result, our bodies developed a survival instinct to eat whenever food is available and store energy as fat, preparing for potential future famines.

How has modern biotechnology influenced the management of appetite and weight?

Modern biotechnology has re-engineered a hormone called GLP-1 that regulates appetite. Originally, GLP-1 breaks down in two minutes, but scientists have extended its lifespan to up to a week, allowing it to effectively control hunger and aid in weight loss.

What is the difference between the past and present in terms of fat storage and survival?

In the past, being overweight was seen as a survival advantage because it meant having stored energy in case of famine. However, in the present, where food is abundant, excess fat leads to health problems such as heart disease, diabetes, and stroke.

What is the main issue with current weight loss drugs like Wegovy?

One significant issue with current weight loss drugs like Wegovy is that they cause muscle loss along with fat loss. This is particularly harmful to older adults, as muscle loss can lead to severe health issues like broken bones and an increased risk of death.

What is the 'biological caste system' mentioned in the script?

The 'biological caste system' refers to the emerging divide between the wealthy, who can afford advanced weight loss drugs and other biotechnology treatments, and the poor, who continue to suffer from obesity and its related health issues due to a lack of access to such treatments.

What role does AI play in the development of weight loss drugs?

AI is being used to simulate and optimize the drug development process, specifically in the design of pills that can effectively suppress appetite over an extended period. This integration of AI into biotechnology is key to enhancing the efficacy and convenience of weight loss medications.

Why are companies like Lilly and Novo Nordisk considered leaders in this field?

Lilly and Novo Nordisk are considered leaders because they have successfully developed drugs that not only promote weight loss but also address other health issues, such as reducing the risks of heart attack, stroke, and kidney failure. Their dominance in this field is compared to the role of major tech platforms like iOS and Android.

What is the significance of companies like Samsung Biologics in the weight loss drug industry?

Samsung Biologics plays a crucial role in the production of weight loss drugs by providing the manufacturing capacity needed to meet the growing demand. As demand for these drugs increases, companies like Samsung will be essential in scaling production to meet global needs.